Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2022-02-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于非经营性资金占用事项自查及整改情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jiangsu Haoubo Biopharmaceutical Co., Ltd. regarding a self-inspection and rectification of non-operating fund occupation involving related parties. It details the specific incident, corrective measures, and an apology statement. The content focuses on disclosure of a financial irregularity and the company's response, rather than presenting financial statements, audit results, or detailed financial data. The document length is short (1542 characters) and it is a regulatory announcement about internal control and compliance issues. It does not fit categories like Annual Report, Interim Report, or Audit Report. It is not a voting result, capital change, or management change announcement. The best fit is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance disclosures that do not fit other categories.
2022-02-18 Chinese
江苏浩欧博生物医药股份有限公司关于收到上海证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Haoubo Biopharmaceutical Co., Ltd. regarding a formal inquiry letter received from the Shanghai Stock Exchange about non-operating fund occupation issues. It details the inquiry content, requests for self-examination, disclosure of related transactions, internal control measures, and responses from auditors and sponsors. The document is a regulatory announcement about an inquiry and related compliance matters, not a financial report, audit report, or earnings release. It does not contain financial statements or detailed financial data but is a regulatory disclosure of an inquiry and the company's planned response. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (1276 characters), and it is not a report publication announcement but a regulatory announcement.
2022-02-18 Chinese
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司高级管理人员、核心技术人员离职暨认定核心技术人员的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Huatai United Securities regarding the departure of a senior management and core technical personnel at Jiangsu Haoubo Biopharmaceutical Co., Ltd. It includes biographical details, impact assessment on the company, and measures taken. The content focuses on personnel changes and their implications rather than financial results, governance rules, or regulatory filings. It is not a full annual or interim report, nor an earnings release or audit report. The document is a formal announcement about management changes, specifically senior management and core technical staff departure and succession. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 4032 characters, which is sufficient for a detailed announcement but not a full financial report. No financial statements or financial data are included, so it is not an IR or 10-K. No voting results or proxy materials are present, so not DVA or PSI. No merger or capital change information is included. Hence, the classification is MANG with high confidence.
2022-02-08 Chinese
江苏浩欧博生物医药股份有限公司关于高级管理人员、核心技术人员离职暨认定核心技术人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the resignation of a senior management member and core technical personnel, Mr. Zhang Hewen, and the recognition of another core technical personnel. It details the departure, the impact on the company, and the company's measures to address the change. The document does not contain financial statements or detailed financial performance data. It is focused on management changes and personnel updates at the senior level. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3189 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-02-07 Chinese
江苏浩欧博生物医药股份有限公司第二届董事会第十三次会议独立董事意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the appointment of senior management personnel at a board meeting. It references compliance with company law and stock exchange listing rules, and discusses qualifications and appointment procedures for vice general managers. The document is not a full annual report, audit report, or financial statement. It is a board/management related announcement about management appointments. The document length is short and focused on management changes, fitting the Board/Management Information category (MANG).
2022-02-07 Chinese
江苏浩欧博生物医药股份有限公司关于聘任证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a securities affairs representative (谢爱香女士) by the company's board. It includes details about the individual's qualifications, contact information, and a brief resume. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The content is about a management/board-related personnel appointment. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this appointment, confirming it is not a report or announcement of a report publication.
2022-02-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.